SignalCorporate
MacroGenics (MGNX) Reports Q3 Loss, Lags Revenue Estimates
MacroGenics Q3 loss and revenue miss versus estimates drove negative sentiment.
Context
What happened: MacroGenics ($MGNX) reported a Q3 loss of $0.34 per share versus the Zacks Consensus Estimate of a $0.10 loss, and revenue of $18.67 million missed the consensus estimate.
Key numbers: Loss of $0.34 per share vs. $0.10 expected; earnings surprise of -240.00%; revenue $18.67 million, missing estimate by 69.89%; year-ago revenue $72.84 million; shares up about 44.1% since the start of the year vs.
Why it matters: The stock carries a Zacks Rank #3 (Hold), and the report notes that near-term price movement will depend mostly on management's commentary on the earnings call.
Market: -0.6% today ($100.99), +6.0% YTD, 0.4x vol — as of 00:45 UTC
Coverage: 4 outlets in 24h
What changed
MacroGenics ($MGNX) reported a Q3 loss of $0.34 per share versus the Zacks Consensus Estimate of a $0.10 loss, and revenue of $18.67 million missed the consensus estimate.
Why it matters
The stock carries a Zacks Rank #3 (Hold), and the report notes that near-term price movement will depend mostly on management's commentary on the earnings call.
Market: -0.6% today ($100.99), +6.0% YTD, 0.4x vol — as of 00:45 UTC